Solvay Pharmaceuticals, Gmbh

Abbott Products Gmbh

Michael Firnges

Jochen Antel

Peter-Colin Gregory

Dania B Reiche

Uwe Schoen

Harald Waldeck

Holger Sann

Michael Wurl

Josephus Hubertus Maria Lange

Reinhard Brueckner

Daniel Jasserand

Uwe Reinecker

Reinhard Brückner

Dania Reiche

Described is a novel combination therapy for diabetes mellitus type I and/or for obesity and its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, by administering a combination of at least one Kchannel opener as a first active agent and at least one CBcannabinoid receptor antagonist as a second active agent. The invention is further directed to such novel combination therapy wherein a dually acting compound with combined Kchannel opening and CBantagonistic properties is used. The invention also relates to novel pharmaceutical compositions comprising Kchannel openers and CBantagonists and the use of said pharmaceutical compositions in the treatment, delayed progression, delayed onset of and/or inhibition of diabetes mellitus type 1, and the prophylaxis and treatment, of obesity as well as the prophylaxis, treatment, delayed onset and/or inhbition of its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, in mammals and humans. The invention is further directed to such novel pharmaceutical compositions comprising a dually acting compound with combined Kchannel opening and CBantagonistic properties.

Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions

The present invention relates to novel N-sulfamoyl-piperidineamides of Formula I and their physiologically acceptable acid addition salts, to pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment of obesity and its concomitant and/or secondary diseases and related or other conditions. 

N-sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions

Described herein are pharmaceutical compositions comprising therapeutically effective quantities of (i) a Kchannel modulator; and (ii) a CBmodulator. Also described herein are methods of making and using these compositions.

Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators

3-cyanonaphthalene-1-carboxylic acid perhydroxyalkylmethyl-piperazine compounds of formula I which are antagonistic to tachykinin receptors, pharmaceutical compositions containing such compounds, methods of using such compounds for the treatment and/or inhibition of various diseases and disorders, processes for preparing such piperazine compounds, and intermediate products of these processes.

NK1 and NK2-antagonists and compositions and methods of using the same

N-sulfamoyl-N'-benzopyranpiperidine compounds of formula I and their physiologically acceptable acid addition salts, pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment and/or inhibition of glaucoma, epilepsy, bipolar disorders, migraine, neuropathic pain, obesity, type II diabetes, metabolic syndrome, alcohol dependence, and/or cancer, and related concomitant and/or secondary diseases or conditions 

N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof

Growing community of inventors

Barsinghausen, Germany

Michael Firnges